Amarin Corporation(AMRN) - 2025 Q4 - Earnings Call Presentation

EVIDENCE-BASED THERAPY TO REDUCE LIFE-THREATENING CARDIOVASCULAR EVENTS Company Overview NASDAQ: AMRN FEBRUARY 2026 Forward Looking Statements & Disclaimer This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (icosapent ethyl) (VAZKEPA® in Europe and in other territories), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, generic product launches, research and development, intellectual property and liti ...